002020 京新药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)5.94312.84412.40111.61313.235
总资产报酬率 ROA (%)4.3749.1318.6488.0649.522
投入资产回报率 ROIC (%)5.42511.55710.97510.13011.708

边际利润分析
销售毛利率 (%)50.50250.14949.97450.57353.275
营业利润率 (%)21.16321.19920.28617.85720.017
息税前利润/营业总收入 (%)20.73620.13018.74616.36017.937
净利润/营业总收入 (%)17.91218.84017.29315.59017.668

收益指标分析
经营活动净收益/利润总额(%)105.81597.29193.43989.23292.627
价值变动净收益/利润总额(%)-0.9503.075-3.9596.1035.780
营业外收支净额/利润总额(%)-1.9410.1930.044-0.850-0.840

偿债能力分析
流动比率 (X)2.4821.7311.3611.6161.807
速动比率 (X)1.9721.3290.9891.3021.381
资产负债率 (%)24.07127.73729.22130.63129.753
带息债务/全部投入资本 (%)2.8173.9425.5666.4526.879
股东权益/带息债务 (%)3,262.1392,300.4061,604.4891,358.4101,261.677
股东权益/负债合计 (%)313.447258.871240.923225.326234.920
利息保障倍数 (X)-874.189-18.139-12.098-12.154-9.375

营运能力分析
应收账款周转天数 (天)68.54567.81157.10547.07944.518
存货周转天数 (天)143.262138.318125.062129.902147.920